Clinical trials: Nash
Obesity
Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
This is a comparison of metformin versus placebo in NASH patients receiving bariatric surgery for obesity.
- Trial name
- NCT00134303
- Testing
- Metformin
- Where
- Belgium
- Volunteers
- 65 people
- Sponsor
- University Hospital, Ghent
Non-Alcoholic Fatty Liver Disease, Obesity
Direct Versus Indirect Effect of Amino Acids on Hepatokines
Liver hormones are key metabolic regulators and increased in metabolic diseases, including fatty liver disease. The underlying mechanisms driving the elevated levels are currently unknown and presents a major challenge in…
- Trial name
- Diaakine (NCT06240039)
- Testing
- Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Diabetes Mellitus, Type 2
Effect of Low-glycemic Index Meals Intake on DM2 Women Under Metformin Therapy
To compare the effect of low-glycemic index versus control lunches and dinners intake on indicators of satiety, metabolic parameters and liver steatosis degree on women with type 2 diabetes under metformin therapy.
- Trial name
- LGIM (NCT03165877)
- Testing
- Low-glycemic index, Control
- Volunteers
- 13 people
- Sponsor
- Universidad de Valparaiso
Non-alcoholic Fatty Liver Disease (NAFLD)
Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)
This study will assess the inter-center reproducibility and accuracy of hepatic fat fraction measurements using up to two MRI-based methods.
- Trial name
- NCT01110577
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Trial name
- NCT06482112
- Testing
- Efinopegdutide
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis
Genetic Studies of Non-Alcoholic Fatty Liver Disease
Background: Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions.
- Conditions
- Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01629095
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Non-alcoholic Fatty Liver Disease
Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver
We are doing this research study to evaluate whether continuous positive airway pressure (CPAP), a treatment for sleep apnea, will also help treat fatty liver disease.
- Trial name
- NCT01849081
- Testing
- CPAP, LIfestyle
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Fatty Liver, Dyslipidemias
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
The purpose of the study is to compare the impact of atorvastatin 20mg qd and Vitamin E 300mg qd therapy on liver fat content in patients with type 2 diabetes associated with high LDL-C and non-alcoholic fatty liver disease.
- Conditions
- Fatty Liver, Dyslipidemias, Diabetes Mellitus
- Trial name
- NCT01720719
- Testing
- atorvastatin, Vitamin E
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xin Gao
Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD)
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), Liver Fibrosis
- Trial name
- SOPRANO (NCT05699018)
- Testing
- eLIFT
- Where
- 13 sites in France
- Volunteers
- 1,788 people
- Sponsor
- University Hospital, Angers
Non-alcoholic Steatohepatitis (NASH)
Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH
The primary objectives of this study are to evaluate the effect of ESG with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) compared to LSG on 1) histological improvement in NASH; 2) all-cause mortality and liver-related…
- Trial name
- TESLA-NASH (NCT04060368)
- Testing
- Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications, Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
NASH - Nonalcoholic Steatohepatitis
Ascending Dose Study of HU6 in Healthy Volunteers
This is a single ascending dose trial in healthy volunteers. The study will be conducted in up to 7 cohorts. Upon review of the safety and PK data, it may be decided to expand the current cohort versus dose escalate to the next…
- Trial name
- NCT04463017
- Testing
- HU6
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
NAFLD (Nonalcoholic Fatty Liver Disease), Hep A
Comparative Effects of Mediterranean and DASH Diet on Hepatic Function
Participants were assigned into three groups Control group recieving general dietary guidelines, Mediterranean diet intervention group DASH dietary intervention group
- Trial name
- NCT07622680
- Testing
- Dietary guidelines for fatty liver, Mediterranean diet, DASH diet
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- University of Lahore
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Fatty Liver, Nonalcoholic
Efficacy and Safety of Fermented Ginseng Powder on Liver Function
This study was conducted to investigate the effects of daily supplementation of fermented ginseng powder on improvement of Liver function.
- Trial name
- NCT03260543
- Testing
- fermented ginseng powder
- Where
- South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
NAFLD, NASH - Nonalcoholic Steatohepatitis
Development and Validation of a Multi-target, Blood-based NAFLD Diagnosis Test
Multi-omics approach was used to identify patterns of serological biomarkers to diagnose NAFLD. The purpose of this study is to develop and validate a blood-based assay to diagnose NAFLD by collecting blood sample from healthy…
- Trial name
- NCT05108415
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- HBI Solutions Inc.
Nonalcoholic Steatohepatitis
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
- Trial name
- AURORA (NCT03028740)
- Testing
- Cenicriviroc
- Where
- 346 sites in United States, Australia and 26 more
- Volunteers
- 1,778 people
- Sponsor
- Tobira Therapeutics, Inc.
DIABETES MELLITUS
The Effect of Vitamin D Supplementation in Type 2 Diabetes
In many observational studies, vitamin D deficiency is related to glucose intolerance and diabetes. But there little randomized, controlled interventional studies that evaluate the effect of vitamin D in type 2 diabetes.
- Trial name
- VD2000 (NCT01854463)
- Testing
- Vitamin D3
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Nonalcoholic Fatty Liver, Metabolic Syndrome
Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Non-invasive diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain unmet medical needs. Aim of this study is to investigate the blood levels of three hormonal systems related to obesity, insulin resistance…
- Trial name
- NAFLD (NCT03986684)
- Where
- Greece
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hippocration General Hospital
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver…
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT07518784
- Testing
- LiverScope® exam, MR exam, Blood draw
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Diego
Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
A total of 195 adult patients with biopsy-proven or clinically diagnosed metabolic dysfunction-associated with fatty liver disease(MAFLD)-related cirrhosis will be randomly divided into two arms.
- Trial name
- NCT06773221
- Testing
- Chiglitazar 64mg
- Where
- 4 sites in China
- Volunteers
- 195 people
- Sponsor
- Beijing Friendship Hospital